Orfoxen 0.8 mg (Orforglipron INN) | Nasima Pharma
WORLDWIDE DOORSTEP DELIVERY

Home Medicines Orfoxen 0.8 mg (Orforglipron INN)

Buy Orfoxen 0.8 mg (Orforglipron INN) - Orforglipron INN Online
Gallery Image
Gallery Image
Gallery Image
Gallery Image

Scan to Connect

WhatsApp Support QR

WhatsApp

WeChat Support QR

WeChat

Orfoxen 0.8 mg (Orforglipron INN)

| In Stock

Generic Name

Orforglipron INN

Manufacturer

Everest Pharmaceuticals Ltd.

Pack Size

30's

Shelf Life

24 Months

Category

ANTI DIABETES

Price on Request Wholesale

Prices vary by country and quantity. Contact us for a quote.

Description

Orfoxen 0.8 mg (Orforglipron INN) – Everest Pharmaceuticals Ltd.

Oral GLP-1 Receptor Agonist for Type 2 Diabetes and Weight Management


📌 Indications:

Orfoxen 0.8 mg is indicated as an adjunct to diet and exercise for:

  • Type 2 Diabetes Mellitus
  • Improvement of glycemic control in adults
  • Weight management in overweight or obese patients (as clinically appropriate)

💊 Pharmacology:

Orforglipron is a non-peptide GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety. These actions contribute to improved blood glucose control and clinically meaningful weight loss.


💉 Dosage & Administration:

  • Administer orally once daily, with or without food.
  • Dose titration should be individualized based on patient response and tolerability.
  • Follow the prescribing physician's recommendations.
  • Continue treatment along with appropriate dietary and lifestyle modifications.

⚠️ Precautions & Warnings:

  • Monitor blood glucose levels regularly.
  • Use with caution in patients with a history of pancreatitis.
  • Gastrointestinal adverse effects may occur, especially during dose escalation.
  • Risk of hypoglycemia may increase when combined with insulin or sulfonylureas.
  • Patients with severe gastrointestinal disease should be monitored carefully.

❌ Contraindications:

  • Hypersensitivity to Orforglipron or any component of the formulation.
  • Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), if applicable according to local prescribing information.

🤰 Pregnancy & Lactation:

  • Use during pregnancy only if clearly needed.
  • Breastfeeding is not recommended during treatment.
  • Women of childbearing potential should consult their physician before use.

⚕️ Side Effects:

Common adverse effects include:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal discomfort
  • Decreased appetite

Serious but uncommon adverse effects may include:

  • Pancreatitis
  • Severe gastrointestinal reactions
  • Hypoglycemia (when used with insulin or sulfonylureas)

🧊 Storage Conditions:

  • Store below 30°C in a cool and dry place.
  • Protect from excessive heat, moisture, and direct sunlight.
  • Keep out of reach of children.

Similar Medicines

Contact Support